PDF(Sci-hub)
Abstract：
OBJECTIVE: A meeting of a Canadian group with significant experience and knowledge in HIV management, consisting of five physicians, a pharmacist and an AIDS researcher, was convened. Their goal was to develop guidance for Canadian HIV-treating physicians on the appropriate use of raltegravir (MK-0518, Isentress(R), Merck Frosst Canada Inc) in HIV-infected adults.
METHODS: Evidence from the published literature and conference presentations, as well as expert opinions of the group members, was considered and evaluated to develop the recommendations. Feedback on the draft recommendations was obtained from this core group, as well as from five other physicians and scientists across Canada with expertise in HIV treatment and antiretroviral drug resistance, and experience in the use of raltegravir. The final recommendations represent the core group\'s consensus agreement once all feedback was considered.
CONCLUSIONS: Recommendations were developed to guide physicians in the optimal use of raltegravir. The issues considered included raltegravir\'s role in overall treatment strategy, efficacy, durability of effect, rate of viral load reduction, resistance, safety/toxicity, pharmacokinetics and drug interactions.
METHODS: Evidence from the published literature and conference presentations, as well as expert opinions of the group members, was considered and evaluated to develop the recommendations. Feedback on the draft recommendations was obtained from this core group, as well as from five other physicians and scientists across Canada with expertise in HIV treatment and antiretroviral drug resistance, and experience in the use of raltegravir. The final recommendations represent the core group\'s consensus agreement once all feedback was considered.
CONCLUSIONS: Recommendations were developed to guide physicians in the optimal use of raltegravir. The issues considered included raltegravir\'s role in overall treatment strategy, efficacy, durability of effect, rate of viral load reduction, resistance, safety/toxicity, pharmacokinetics and drug interactions.
摘要：
目标：在艾滋病毒管理方面具有丰富经验和知识的加拿大小组会议，由五名医生组成，药剂师和艾滋病研究人员，被召集。他们的目标是为加拿大艾滋病毒治疗医生制定适当使用raltegravir的指导（MK-0518，Isentress（R），加拿大默克弗罗斯特公司)在感染艾滋病毒的成年人中。
方法：来自已发表文献和会议报告的证据，以及小组成员的专家意见，进行了审议和评估，以制定建议。从该核心小组获得了对建议草案的反馈，以及来自加拿大其他五位在艾滋病毒治疗和抗逆转录病毒药物耐药性方面具有专业知识的医生和科学家，和使用雷替格韦的经验。一旦考虑了所有反馈，最终的建议代表了核心小组的共识。
结论：制定了建议以指导医生最佳使用雷替格韦。考虑的问题包括raltegravir在整体治疗策略中的作用，功效,耐久性的效果，病毒载量降低率，阻力,安全性/毒性，药代动力学和药物相互作用。
方法：来自已发表文献和会议报告的证据，以及小组成员的专家意见，进行了审议和评估，以制定建议。从该核心小组获得了对建议草案的反馈，以及来自加拿大其他五位在艾滋病毒治疗和抗逆转录病毒药物耐药性方面具有专业知识的医生和科学家，和使用雷替格韦的经验。一旦考虑了所有反馈，最终的建议代表了核心小组的共识。
结论：制定了建议以指导医生最佳使用雷替格韦。考虑的问题包括raltegravir在整体治疗策略中的作用，功效,耐久性的效果，病毒载量降低率，阻力,安全性/毒性，药代动力学和药物相互作用。
